{"id":"NCT00980005","sponsor":"GlaxoSmithKline","briefTitle":"Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children","officialTitle":"Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10-13","primaryCompletion":"2010-03-02","completion":"2010-06-17","firstPosted":"2009-09-18","resultsPosted":"2012-02-15","lastUpdate":"2018-09-21"},"enrollment":2116,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"GSK investigational vaccine GSK1557482A","otherNames":[]},{"type":"BIOLOGICAL","name":"FluzoneÂ®","otherNames":[]}],"arms":[{"label":"Flulaval Group","type":"EXPERIMENTAL"},{"label":"Fluzone Group","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK1557482A.","primaryOutcome":{"measure":"Geometric Mean of Haemagglutination Inhibiting (HI) Antibodies Titers Against the Three Strains.","timeFrame":"At Day 0 and 28 after last vaccine dose.","effectByArm":[{"arm":"Flulaval Group","deltaMin":46,"sd":null},{"arm":"Fluzone Group","deltaMin":45.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":9,"exclusionCount":14},"locations":{"siteCount":28,"countries":["United States"]},"refs":{"pmids":["29465480","22333695"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":1055},"commonTop":["Pain","Muscle aches","Fatigue","Headache","Cough"]}}